VEGFR is widely expressed in adenoid cystic carcinoma (ACC). In an open-label, multicenter, phase II clinical trial, Hanna and colleagues demonstrate antitumor activity with rivoceranib, a selective VEGFR-2 tyrosine kinase inhibitor, in patients with recurrent or metastatic ACC who had objective radiographic progression in the preceding 6 months, particularly among VEGFR-naïve patients. Antitumor activity was accompanied by a manageable safety profile consistent with other agents in this class. These findings suggest that selective inhibition of VEGFR-2 represents a potential treatment for ACC warranting further investigation.

Patients with advanced/recurrent endometrial cancer have poor prognoses and limited treatment options following disease progression on frontline therapies. Deficient mismatch repair (dMMR) is a predictive biomarker for response to immune checkpoint inhibitors in endometrial cancer. In this interim analysis of the phase I GARNET trial, Oaknin and colleagues report that patients with advanced/recurrent endometrial cancer who had progressed on or after platinum therapy demonstrated durable...

You do not currently have access to this content.